Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis. (April 2018)

• Record Type: Journal Article
• Authors: Xiao, Wenjing; Guo, Jian-Ping; Li, Chun; Ye, Hua; Wei, Wei; Zou, Yaohong; Dai, Lie; Li, Zhijun; Zhang, Miaojia; Li, Xiangpei; Cai, Xiaoyan; Zhao, Jianhong; Wang, Youlian; Tao, Yi; Liu, Dongzhou; Li, Yasong; Wu, Min; Sun, Erwei; Wu, Lijun; Luo, Li; Mu, Rong; Li, Zhanguo
• Is Part Of: Pharmacogenomics. Volume 19:Number 5(2018)
• Page Start: 383
• Page End: 392
• Publication Date: 2018-04
• Subjects: efficacy -- genetic predictors -- iguratimod -- rheumatoid arthritis -- toxicity; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2017-0162
• Languages: English
• ISSNs: 1462-2416

Abstract

Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety.Aim: The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA.Materials & methods: Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results: ABCG2 rs2231142 A allele conferred a higher response to IGU, while NAT2 rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers.Conclusion: Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.